06/11/2024 - Press release
This study will be conducted in collaboration with the Josep Carreras Leukemia Research Institute, and researchers from Finland, the Netherlands, and the United Kingdom will participate. The goal is to develop and validate protocols and systems for generating laboratory-derived stem cells to regenerate patients' blood. The European Research Council, which provides these grants, is the leading funding organization for advanced and excellent research on the continent. It is an organization created by the European Union.
05/06/2024 - Press release
A scientific team led by Dr Anna Bigas, from the Hospital del Mar Research Institute and the Josep Carreras Institute, has described the role of the IκBα protein in the differentiation process of haematopoietic cells. In the absence of this protein, the stem cells enter quiescence, acquire a dormant state and maintain their potential, which may allow them to be transplanted for therapeutic uses in leukaemia or blood diseases of genetic origin. This is an important step towards being able to generate these types of cells in the lab, preventing them from differentiating and turning into other cells too early.
03/05/2024 - Press release
Natural Killer (NK) cells, when exposed to antibody treatment used against HER2-positive breast cancer, secrete specific types of cytokines that activate the immune response against tumor cells. Researchers have confirmed that patients with NK lymphocytes present in the tumor environment show a better response to treatment, thanks to this mechanism. This confirms the feasibility of using cytokines secreted by NK cells as markers of response to anti-HER2 antibodies with a simple blood test. It also reaffirms various clinical trials using these lymphocytes to bolster treatment in patients with metastatic HER2-positive breast cancer.
15/04/2024 - General information
The Reial Acadèmia de Medicina de Catalunya chose, in a plenary session held on April 9, Dr. Manuel Pera as the new full academician of the institution. Dr. Pera, who was already a corresponding academic since 2022, will be attached to the surgery section of the institution. The section chief of the Gastrointestinal Surgery Unit of the Hospital del Mar and researcher at the center's Research Institute, thus becomes one of the sixty full academicians of the institution. The election is made by a vote among the members themselves. The ceremony of entry into the Royal Academy will take place in the coming months.
16/11/2023 - Institutional news
The Universidad Francisco de Victoria (UFV), in association with the science and technology company MERCK, presents awards to researchers who have made significant clinical and scientific contributions in the field of cancer immunology research.
A study involving the Hospital del Mar Research Institute, the Vall d'Hebron Institut d'Oncologia, IDIBELL, and the Institut Català d'Oncologia suggests that combining chemotherapy with drugs that can inhibit two cell signaling pathways involved in tumor progression may aid in treatment. The research has analyzed the interaction of the protein IKKα with these pathways, known for their ability to promote the proliferation of tumor cells. This combination has the advantage of reducing treatment toxicity. The study opens the door to new approaches for tumors with the presence of this protein. It is published in the EMBO Journal.
Més informació "A possible new combination of treatments to combat cancer"
11/10/2023 - Institutional news
The prizes were awarded at the SEOM congress held in Barcelona at the end of September. The doctoral thesis of Dr. Pedro Rocha, assistant doctor at the Oncology Department of the Hospital del Mar and researcher at the Hospital del Mar Research Institute, has received one of the five grants awarded by the Spanish Society of Medical Oncology (SEOM) to doctoral theses by young researchers. The award ceremony took place on 22 September during the congress of the organisation.
28/06/2023 - General information
The Mutua Madrileña Foundation has awarded its XX Health Research Grants, worth 2.3 million euros, to 26 clinical studies that will be carried out in hospitals throughout Spain. Six of these research projects will be carried out in Barcelona in the areas of cancer immunotherapy, rare childhood diseases, infant and juvenile mental health and transplantation, and together receive funding of more than 680,000 euros. From the Hospital del Mar Research Institute, Doctor Joaquín Arribas, will carry out a study in the field of immunotherapy in cancer. Specifically, it will perform a prospective analysis of biopsies obtained in a phase 1 clinical trial of dose increase using CAR-t Her 2 biospecific cells in patients with advanced solid tumors positive for P95HER2.
21/06/2023 - Press release
The Molecular Mechanisms of Cancer and Stem Cell Research Group of the Hospital del Mar Research Institute is the only center in Spain to participate in an international study that validates the deficiency of a protein, IκBα, as a marker of poor prognosis in this type of tumor The work, published in Cell Reports Medicine, has analyzed data from more than 2,000 patients. In addition, the researchers have identified one of the pathways on which this protein acts, which makes it a possible therapeutic target The Hospital del Mar Research Institute group is already working on a model to search for possible treatments that modulate the function of this marker. It should be considered that at present there are very few therapeutic alternatives for glioma, which has a very high mortality rate
30/03/2023 - Press release
Adding a peptide, a molecule made of several amino acids, to oxaliplatin, a chemotherapy drug used to treat colorectal cancer, avoids the side effects this treatment can have on normal cells, including potential chemotherapy resistance. This is confirmed by an article published in the Journal of Medicinal Chemistry, led by the Hospital del Mar Medical Research Institute and the Institute for Research in Biomedicine (IRB Barcelona). This work is the second part of a recent study that explored how platinum accumulation in normal cells promotes platinum resistance in colorectal cancer cells. This new approach prevents healthy cells surrounding the tumour from accumulating platinum. This avoids the activation of certain genes linked to poor treatment response and tumour progression.
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
